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Recent studies have demonstrated that the depletion of Regulatory T cells (Tregs)
inhibits neural progenitor cell migration after brain ischemia. However, whether Tregs
affect neural stem/progenitor cell proliferation is unclear. We explored the effect of
Tregs on neurogenesis in the subventricular zone (SVZ) after ischemia. Tregs were
isolated and activated in vitro. Adult male C57BL/6 mice underwent 60 min transient
middle cerebral artery occlusion (tMCAO). Then Tregs (1 × 105) were injected into
the left lateral ventricle (LV) of normal and ischemic mouse brain. Neurogenesis was
determined by immunostaining. The mechanism was examined by inhibiting interleukin
10 (IL-10) and transforming growth factor (TGF-β) signaling. We found that the number
of BrdU+ cells in the SVZ was significantly increased in the activated Tregs-treated mice.
Double immunostaining showed that these BrdU+ cells expressed Mash1. Blocking
IL-10 reduced the number of Mash1+/BrdU+ cells, but increased the amount of
GFAP+/BrdU+ cells. Here, we conclude that activated Tregs enhanced neural stem cell
(NSC) proliferation in the SVZ of normal and ischemic mice; blockage of IL-10 abolished
Tregs-mediated NSC proliferation in vivo and in vitro. Our results suggest that activated
Tregs promoted NSC proliferation via IL-10, which provides a new therapeutic approach
for ischemic stroke.
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Introduction
Ischemic stroke leads to irreversible brain injury, because a large number of neurons die during
ischemia. This is a major concern for ischemic patients, and remains elusive to be solved.
Studies have shown that ischemic stroke could induce neurogenesis in animal and human brains
(Hermann et al., 2014; Ruan et al., 2014). Proliferative neural stem cells (NSCs), in response
to ischemic injury, would migrate to damaged regions and then differentiate into the mature
neuronal cells replacing the damaged neurons (Ruan et al., 2014). This phenomenon fascinated a
possibility that neurogenesis could be beneficial to neurological outcomes after ischemia. However,
the mechanism underlying stroke-induced neurogenesis is largely unexplored (Jin et al., 2003).
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Immune cells including regulatory T cells (Tregs) are
activated in response to cerebral ischemia. Tregs are considered
as the crucial cerebral-protective immunomodulator after brain
ischemia (Becker, 2010; Brait et al., 2012; Li et al., 2014), since
the removal of Tregs have been observed to aggravate the
infarct volume and neurological outcomes by acting on many
inflammatory pathways after experimental ischemic stroke (Liesz
et al., 2009). Intravenous administration of Tregs protected brain
tissue via reducing immune cell infiltration, attenuating cerebral
inflammation, and preventing blood barrier disruption following
ischemic stroke (Li et al., 2013a). It is generally believed that
Tregs limit the development of secondary injury by inhibiting
inflammation in the brain which could partly reduce neuronal
cell death. Also, recent data demonstrated that immune cells,
including Tregs, were involved in neurogenesis (Wang and Jin,
2015). Moreover, a recent study showed that the depletion of
Tregs suppressed neurogenesis, along with impaired neurological
recovery (Saino et al., 2010). However, the relationship between
activated Tregs and neurogenesis is still largely unknown.
Interleukin 10 (IL-10) is an anti-inflammatory molecule that
maintains the balance between pro- and anti-inflammation.
Studies have documented that Tregs predominantly produce
IL-10 (Murray, 2006; Saraiva and O’Garra, 2010; Ouyang
et al., 2011) which stimulates other Tregs to secrete more
IL-10, creating a positive feedback loop (Barrat et al., 2002).
This would be important, because IL-10 might play a
role in regulating neurogenesis after brain injury. Injecting
IL-10 overexpressed NSCs into the experimental autoimmune
encephalitis (EAE) mice not only inhibited inflammatory
response, but also promoted the differentiation of transplanted
NSCs into oligodendrocytes and neurons (Yang et al., 2009).
In the present study, we did not detect endogenous
Tregs infiltration into the ischemic brain physiologically. We
transplanted exogenous Tregs into the lateral ventricle (LV) as a
therapeutic intervention to explore the effect of Tregs on the NSC
proliferation in the SVZ. We explore the effect of activated Tregs
on the proliferation of NSCs in the subventricular zone (SVZ)
of the normal and ischemic mouse brain and to determine the
mechanism underlying Tregs-mediated neurogenesis in mice.
Materials and Methods
Experimental Design
Animal studies were conducted in accordance with ARRIVE
guidelines. Procedure for the use of laboratory animals was
approved by the Institutional Animal Care and Use Committee
(IACUC) of Shanghai Jiao Tong University, Shanghai, China.
In the animal studies, guidelines of the regulation for the
administration of affairs concerning experimental animals of
China enacted in 1988 were followed. Mice were housed under
standard laboratory conditions. Adult male C57BL/6 mice (8–12
weeks) weighing between 25–30 g were used in the experiments.
Tregs were isolated from adult C57BL/6 and GFP C57BL/6
mice and then activated in vitro. Mice underwent MCAO at
day 0, followed by Tregs injection into LV at day 1. BrdU
was administrated by intraperitoneal injection daily for 3 days.
Finally, mice were sacrificed and brain samples were sectioned
for immunostaining (Figure 3A). In the first experiment, mice
were randomly divided into three groups (n = 5 for normal mice,
n = 5–10 for MCAOmice): (1) Vehicle group, mice injected with
PBS; (2) U-Treg group, mice injected with un-stimulated Tregs;
and (3) A-Treg group, mice injected with activated Tregs. In
the second experiment, mice were randomly divided into three
groups (n = 5 per group): (1) A-Treg group, mice injected with
activated Tregs; (2) A-Treg/Anti-IL-10 group, mice injected with
activated Tregs plus IL-10 neutralizing antibody (Ebioscience,
Franklin Lakes, NJ, USA); and (3) A-Treg/Anti-transforming
growth factor (TGF-β) group, mice injected with activated Tregs
plus TGF-β neutralizing antibody (R&D, Minneapolis, MN,
USA). 5-bromodeoxyuridine (BrdU, 50 mg/kg, twice/day) was
administrated intraperitoneally after Treg injection for 3 days to
label proliferative stem cells in the SVZ of mice. Neurological
severity scores (NSS) and evaluated body swing test (EBST)
were applied to detect the neurological behavior of MCAOmice.
Animals were sacrificed under deep anesthesia 3 days after Tregs
transplantation. Infarct volumes were then evaluated by cresyl
violet staining, and NSC proliferation was further determined
by immunohistochemistry. In in vitro experiment, neurospheres
isolated from the brain cortex of 14 days fetal normal mice were
randomly divided into three groups (n = 6 per group): (1) control
group: neurospheres cultured in the normal medium; (2) A-Treg
group: neurospheres co-cultured with activated Tregs; and (3) A-
Treg /anti-IL-10 group: neurospheres co-cultured with activated
Tregs plus IL-10 neutralizing antibody. The number and size of
neurospheres were statistically analyzed after 3-day co-culturing.
In in vivo study, 1 × 105 cells (Sun et al., 2008) in 5 µl PBS were
stereotaxically injected into the left LV (AP =−0.2 mm,ML =−1
mm, DV = −2.5 mm). The volume of neutralizing antibody IL-
10 (10 µg/ml) and TGF-β (10 µg/ml) were 5 µl. In in vitro study,
the concentration of IL-10 neutralizing antibody was 10 µg/ml.
Tregs Isolation, Identification and Activation
Firstly, splenocytes were isolated from adult C57BL/6 and GFP
C57BL/6 mice by pressing spleens through 70 µm filters (BD
Bioscience, San Jose, CA, USA). Secondly, CD4+ T cells were
sorted using Mouse CD4+ T cell Pre-enriched Kit (Stemcell,
Vancouver, BC, Canada) via magnetic activated cell sorting
(MACS). CD4+/CD25+ Tregs were then enriched from CD4+
T cells by Flow Activated Cell Sorter (FACS; BD Bioscience)
after being labeled with PE anti-mouse CD25 (Biolegend, San
Diego, CA, USA). Enrichment of CD4+/CD25+ Tregs was
further confirmed by Foxp3 staining (Biolegend). These cells
were then cultured in the presence of anti-mouse CD28 (2
µg/ml, Ebioscience) and recombinant mouse IL-2 (400 U/ml,
Life Technologies, Grand Island, NY, USA) in cell culture
plates pre-coated with anti-mouse CD3e (10 µg/ml, Ebioscience,
Franklin Lakes, NJ, USA). Three days later, CD44 and CD62L
(Biolegend) staining were performed to confirm Treg activation.
At the same time, mRNA level of IL-10, TGF-β and epstein-barr
virus induced gene-3 (ebi3) were evaluated by qRT-PCR.
qRT-PCR
Total RNAs were extracted using an Arcturusr Picopurer RNA
Isolation Kit and were reversely transcribed to cDNAs using a
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SuperScriptr First-Strand Synthesis System according to the
manufacture’s instructions. Real-time PCR was performed using
a Power SYBRr Green Master Mix on a 7300 real-time PCR
System. Reagents and kits for PCR were all purchased from
Life Technologies. Data were analyzed on 7300 system software.
Primer sequences (Sigma-Aldrich, St. Louis, MO, USA) for each
gene were shown as follows:
IL-10: Forward: 5′AGGCGCTGTCATCGATTTCT3′
Reverse: 5′ATGGCCTTGTAGACACCTTGG3′
TGF-β : Forward: 5′ATGGCGCAAAACAGTCCACA3′
Reverse: 5′TGTAACATGCACTGGGATACCA3′
ebi3: Forward: 5′CGCTCCCCTGGTTACACTG3′
Reverse: 5′CCACGGGATACCGAGAAGC3′
β -actin: Forward: 5′CTGTCGAGTCGCGTCCA3′
Reverse: 5′CGCAGCGATATCGTCATCCA3′
The accession number of target genes is IL-10: NM_010548.2,
TGF-beta: NM_011577.1, ebi3: NM_015766.2, Beta-actin:
NM_007393.4.
Transient MCAO (tMCAO) in Mice
Transient MCAO were performed as previously described (Chen
et al., 2014). Briefly, mice were anesthetized with 1.5–2%
isoflurane, 30% oxygen and 70% nitrous oxide. After exposing
internal carotid artery, left external carotid artery and left
internal carotid, a 6–0 silicone-coated suture (Doccol, Beijing,
BJ, China) was inserted from ECA into ICA to occlude the
origin of middle cerebral artery. A successful of occlusion was
confirmed by a laser Doppler flowmetry (Perimed AB, Järfälla,
Sweden) with a decrease of 80% compared to the baseline blood
flow. Reperfusion was performed by suture withdrawing alone
an hour after occlusion. Blood flow returned to the 70% of
baseline was considered successful reperfusion. Sham operated
mice underwent the same procedure without inserting the suture.
Immunochemistry
Mice were euthanatized under deep anesthesia. Brains were
removed after 0.9% sodium chloride and 4% paraformaldehyde
perfusion. After fixation at 4◦C overnight, brains were embedded
in paraffin and were cut into 5-µm sections. Brain slices were
then incubated with antibodies against BrdU (1:500, mouse,
Sigma-Aldrich), DCX (1:200, rabbit, Millipore, Boston, MA,
USA), GFAP (1:200, goat, Santa Cruz, Dalas, TX, USA) and
Vimentin (1:100, rabbit, Abcam, Cambridge, MA, USA) at 4◦C
overnight, followed by incubation of secondary antibodies (Life
Technologies) for 1 h. Negative controls (omit primary antibody)
were performed for each staining to avoid bleed through.
For Mash1 (1:100, mouse, BD Bioscience, CA, USA) staining,
brain slices were incubated with Biotin/Avidin blocking solution
(Vector Lab, Burlingame, CA, USA) for 10 min before serum
blocking. After incubating with biotinylated secondary antibody
(Vector Lab), Avidin DCS (Vector Lab) was added and
incubated with the samples for 10 min. Following steps were
the same as above described. Results were observed under an
inverted fluorescence microscope (Zeiss, Thornwood, NY, USA).
Photomicrographs were taken to identify and count cells. The
positive cells were counted in five immunofluorescent or DAB
slices per animal, spaced 100 µm apart.
Infarct Volume Measurement
Mice were sacrificed 3 days after cell injection. Brains were
removed and frozen immediately in isopentane. A series of
20-µm-thick coronal sections from anterior commissure to
hippocampus were cut and stained with cresyl violet. Sections
were photographed and digitized using Image J software. Infarct
volume was then calculated as previously described (Huang et al.,
2010).
Neurobehavioral Tests
Mice underwent modified NSS and EBST tests 1 day after
transient middle cerebral artery occlusion (tMCAO) and 1, 2,
3 days after Treg injection. For modified NSS (normal score,
0; maximal deficit score, 14), the flexion of forelimb and
hindlimb was observed by lifting the tail of the mice (0–3);
walk-posture of the mice was observed by being placed on the
floor (0–3); the balance ability was evaluated by putting the
mice on a beam (0–6); the reflexes absence was detected by
pinna reflex and corneal reflex. For EBST test, the mice were
held at the tail and raised 10 cm above the testing surface.
The number of wing direction (right or left) was recorded in
20 trials per mouse. The percentage of right biased wing was
calculated.
Neurosphere
NSCs were isolated from E14 C57BL/6 mice and cultured in
DMEM/F12 medium including B27 (2%), bFGF (20 ng/ml), and
EGF (20 ng/ml, Life Technologies) as previously described (Tang
et al., 2014). Neurospheres from passage 2 were then co-cultured
with activated Tregs at a ratio of 2:1.
Statistical Analysis
Data were presented as mean± SD. Data from cell identification,
cytokine mRNA levels and the number of BrdU+ and DCX+
cell comparison between sham and tMCAO mice were analyzed
by student t test. Data among sham, un-activated and activated
Tregs were analyzed by one-way analysis of variance (ANOVA),
followed by Turkey post hoc comparisons. p < 0.05 was
considered statistically significant.
Results
Treg Identification and Activation
CD4+/CD25+ T cells are defined as Tregs (Khattri et al., 2003).
To quickly obtain pure CD4+/CD25+ Tregs, we firstly enriched
CD4+ T cells using MACS, and then isolated CD4+/CD25+
Tregs by FACS. Compared to the enriched CD4+ T cells, the
percentage of CD4+/CD25+ T cells was higher after MACS
and FACS, reaching 97% (Figure 1A). To further confirm the
Treg identity, Foxp3, the master regulator of Tregs (Hori et al.,
2003), was detected against sorted CD4+/CD25+ T cells by flow
cytometry analysis (Figure 1A). The result demonstrated that
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FIGURE 1 | Tregs were identified by CD4/CD25 and activated by
CD3e/CD28/IL-2. (A) CD4+/CD25+ Tregs isolated from mouse spleen were
analyzed by a flow cytometry sorting (FACS). CD4+/CD25+ (b) and Foxp3 (d)
were detected after CD4+/CD25+ Tregs isolation via magnetic activated
cytometry sorting (MACS) and FACS, enriched CD4+ T cells isolated by
MACS being used as the control (a,c). (B) CD44 (a,c) and CD62L (b,d)
expression on Tregs after activation. Peripheral blood was used as the control.
Data were mean ± SD, using the student t test. N = 3 per group. ∗∗ p < 0.01,
A-Treg group vs. Control group. (C) IL-10 (a), TGF-β (b) and ebi3 (c) mRNA
expression of un-stimulated and activated Tregs were quantified by qRT-PCR.
Data were mean ± SD, using the student t test. N = 5–7 per group. ∗∗p <
0.01, A-Treg group vs. U-Treg group. U-Treg, un-stimulated Tregs; A-Treg,
activated Tregs.
Foxp3 expressed in most of CD4+/CD25+ Tregs after MACS
and FACS; the percentage was about 69.1%. Since about 20% of
live cells were dead in FACS, the actual percentage of Foxp3+
cells would be higher than 69.1%. These results suggested that
most of cells we isolated from spleenwere CD4+/CD25+/Foxp3+
Tregs.
To activate Tregs, CD3e Ab, CD28 Ab, and IL-2 were
administered to stimulate CD4+/CD25+ Tregs for 3 days. CD44
and CD62L expressions were measured by flow cytometry.
Student t test was used to analyze the difference between the
control and activated Tregs groups. The results demonstrated
that the Tregs significantly up-regulated CD44 (80.0%) and
down-regulated CD62L (1.2%) after stimulation (Figure 1B),
indicating Tregs were indeed activated. On the contrary, Tregs
freshly isolated from blood expressed CD44 at a low level
(4.4%) and CD62L at high level (53.6%; Figure 1B). IL-10,
TGF-β and ebi3 mRNA levels were examined by qRT-PCR to
explore cytokine production in Tregs. Using student t test, we
demonstrated that IL-10 was markedly increased in activated
Tregs compared to un-stimulated Tregs while TGF-β and ebi3
were not altered (Figure 1C). Thus, activated Tregs expressed
high level of IL-10, which might play an important role in the
function of activated Tregs.
Activated Tregs Promoted NSC Proliferation in
the Mouse Brain
PBS, un-stimulated and activated Tregs were injected into the LV
of naïve mice to explore the effect of Tregs on NSC proliferation.
Three days after injection, using the one-way ANOVA with
Turkey post hoc comparisons, we found that BrdU+ cells were
significantly increased in mice receiving activated Tregs, while
there was no change in mice receiving PBS or un-stimulated
Tregs (Figure 2A), which suggested that activated Tregs could
promote NSC proliferation in the SVZ of naïve mice.
NSCs in the SVZ consist of four cell types including A, B,
C and E. To determine which types of NSCs were changed,
we chose four commonly used molecular markers of the four
cell types to double-stain with BrdU. DCX, GFAP, Mash1 and
Vimentin were utilized as the marker to distinguish cell type A,
B, C and E, respectively. As shown in the immunofluorescence
staining, DCX, GFAP and Vimentin were expressed in cytoplasm
while Mash1 was expressed in the cell nucleus (Figure 2B).
By analyzing the percentage of DCX+/BrdU+,
GFAP+/BrdU+, Mash1+/BrdU+ and Vimentin+/BrdU+
cells in BrdU+ cells (Figure 2C), we verified that most BrdU+
cells were DCX+ cells (48.3–55.3%), followed by GFAP+/BrdU+
cells (22.5–32.1%), and then Vimentin+/BrdU+ cells (0.4–1.1%).
Using the one-way ANOVA with Turkey post hoc comparisons,
we further found that Mash1+/BrdU+ cells were significantly
increased in mice receiving activated Tregs (41.0%) compared
to mice receiving PBS (31.1%) or un-stimulated Tregs (28.8%).
Therefore, we confirmed that activated Tregs mainly affected
Mash1+/BrdU+ cells (C cell type), while having no impact on A,
C or E cell types under normal conditions.
Activated Tregs Promoted NSC Proliferation
Following MCAO
Nest, the potential connection between Treg injection and
neurogenesis development in cerebral ischemia was evaluated
next. We performed MCAO to explore the Tregs on NSC
proliferation in the ipsilateral SVZ. Using the student t test,
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FIGURE 2 | Activated Tregs promoted NSC proliferation in the SVZ of
naïve mice. (A) BrdU DAB staining was performed in the Vehicle (b), U-Treg
(c) and A-Treg (d) groups of normal mouse. Scale bar = 50 µm. The number
of BrdU positive cells was counted in the anterior of SVZ (in the black box of
a). Bar graph (e) semi-quantified the number of BrdU+ cell in the Vehicle,
U-Treg and A-Treg groups of naïve mice. Scale bar = 100 µm. Data were
mean ± SD, using the one-way ANOVA followed by Turkey post hoc
comparisons. N = 5 per group. ∗p < 0.05, A-Treg vs. U-Treg and Vehicle
groups. (B) Four types of neural stem cell in (NSC) the mouse SVZ were
identified by immunofluorescence following PBS, un-stimulated and activated
Tregs injecting into lateral ventricle (LV). BrdU double stained with DCX (a–c),
GFAP (d–f), Mash1 (g–i) and Vimentin (j–l) were presented respectively in
Vehicle, U-Treg and A-Treg groups. The arrow indicated the double-stained
positive cells. Scale bar = 50 µm. (C) The percentage of the four cell types in
BrdU+ cells were quantified in Vehicle, U-Treg and A-Treg groups, separately.
Data were mean ± SD, using the one-way ANOVA followed by Turkey post
hoc comparisons. N = 5 per group. ∗p < 0.05, A-Treg group vs. Vehicle and
U-Treg groups. Vehicle, PBS injection; U-Treg, un-stimulated Tregs injection;
A-Treg, activated Tregs injection.
FIGURE 3 | Brain ischemia induced NSC proliferation. (A) Flow chart of
the experiment. Mice underwent MCAO at day 0, followed by Tregs
transcranial injection into LV at day 1. Then BrdU was administrated by
intraperitoneal injection for 3 days. Finally, mice were sacrificed for
immunostaining. (B) Photomicrographs showed BrdU+ cells in the ipsilateral
SVZ in the sham (b) and the MCAO (c) group. The black box (a) represented
the region we are interested and BrdU+ cell counted. (d) Bar graph
demonstrated the number of BrdU+ cells in the sham and the MCAO groups.
Data were mean ± SD, using the student t test. Scale bar = 100 µm. N = 5
per group.∗p < 0.05, MCAO group vs. Sham group. (C) DCX+ cells were
detected by immunostaining in the sham (b) and MCAO (c) groups. The
selected area where we counted DCX+ cells was shown in the black box (a).
Comparison of DCX+ cells number between sham and MCAO group (d).
Scale bar = 100 µm. Data were mean ± SD, using the student t test. N = 5
per group. ∗p < 0.05, MCAO vs. sham and U-Treg groups.
we demonstrated that BrdU+ (Figure 3B) and DCX+ cells
(Figure 3C) were robustly increased in mice after MCAO
compared to the sham mice. This indicated that ischemia
could induce NSC proliferation. Then we injected PBS, un-
stimulated Tregs and activated Tregs into the LV of ipsilateral
hemisphere of mice following MCAO. Using the one-way
ANOVA with Turkey post hoc comparisons, we found that
the number of BrdU+ cells was greatly increased in the mice
receiving activated Tregs compared to those receiving PBS or
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un-activated Tregs (Figures 4A,B), suggesting that activated
Tregs could also promote ischemia-induced NSC proliferation.
We further demonstrated that activated Tregs increased the
number of Mash1+/BrdU+ cells while decreased GFAP+/BrdU+
cells (Figures 4B,C). These results indicated that activated Tregs
could act on the B and C cell types after brain ischemia.
Transplantation of Activated Tregs did not
Improve Stroke Outcomes in Mice
To assess stroke outcomes in tMCAO mice treated with PBS,
un-stimulated Tregs and activated Tregs, we performed cresyl
violet staining to measure the infarct volume (Figures 5A,B) and
neurobehavioral test (Figures 5C,D) to observe the neurological
deficits. Data were analyzed by one-way ANOVA with Turkey
post hoc comparisons in Vehicle, U-Treg and A-Treg groups. We
did not find the difference of infarct volume among three groups.
Similar to the changes of infarct volume, there was no difference
of NSS and EBST tests among three groups.
Tregs were Found in the Lateral Ventricle and
Adjacent Brain Parenchyma after Injection
To determine the location of Tregs after injection, GFP-Tregs
were isolated, activated and injected into the LV as previously
described. Three days after injection, mice brains were removed
and cut. The brain slices were then stained with DAPI and
observed under a fluorescence microscope. GFP-Tregs were
found in the brains of A-Treg and U-Treg groups, but not in PBS
group. Additionally, GFP-Tregs were found to be located in LV
and adjacent brain parenchyma (Figure 6).
Activated Tregs Activated NSCs via IL-10 In Vitro
and In Vitro
Previous studies showed that IL-10 and TGF-β were closely
related to stimulation of neurogenesis locally (Liu et al., 2009;
Kohman and Rhodes, 2013; Casari et al., 2014). Therefore,
we speculated that activated Tregs promote NSC proliferation
through secreting cytokines. We injected activated Tregs plus
IL-10 or TGF-β neutralizing antibodies into the LV of naïve
mice to detect whether blocking either IL-10 or TGF-β would
block the function of activated Tregs (Grossman et al., 2004;
Pineda et al., 2013). Data were analyzed by one-way ANOVA
with Turkey post hoc comparisons in A-Treg, A-Treg/Anti-IL-
10, and A-Treg/Anti-TGF-β groups. The results confirmed that
the administration of activated Tregs plus IL-10 Ab decreased
the proportion of Mash1+/BrdU+ cells in total pool of BrdU+
cells, and meanwhile conversely increased the percentage of
GFAP+/BrdU+ cells (Figure 7A). Blocking TGF-β did not alter
the effect of activated Tregs on NSC proliferation (Figure 7B).
The results suggested that IL-10 played a key role in the
enhancement of NSC proliferation by activated Tregs.
IL-10 neutralizing antibody was added into the activated
Tregs and neurosphere co-culture to verify the role of IL-10
in vitro. Data were analyzed by one-way ANOVA with Turkey
post hoc comparisons in control, A-Treg, and A-Treg/Anti-IL-
10-groups. The results suggested that activated Tregs increased
the number of neurospheres (20–50 µm) compared to those
FIGURE 4 | Activated Tregs promoted NSC proliferation in the SVZ of
mice following middle cerebral artery occlusion (MCAO). (A)
Photograph of immunofluorescence staining showed BrdU+ cells in the SVZ
of MCAO mice treated with PBS (b), un-stimulated Tregs (c) and activated
Tregs (d) injection into the left LV. The black box (a) showed the area we
counted the cells. BrdU+ cell number was quantified in the three groups (e).
Scale bar = 100 µm. Data were presented as mean ± SD, using the one-way
ANOVA followed by Turkey post hoc comparisons. N = 5–10 per group. ∗p <
0.05, A-Treg group vs. U-Treg and Vehicle groups. (B) Double-labeled
fluorescence staining detected the expression of BrdU+/DCX+ (a–c),
BrdU+/GFAP+ B (d–f), BrdU+/Mash1+ C (g–i) and BrdU+/Vimentin+ (j–l) in
SVZ of mice after MCAO in Vehicle, U-Treg and A-Treg groups. The arrow
indicated the positive cells. Scale bar = 50 µm. (C) Statistical analysis of the
percentage of A, B, C and E type in BrdU+ cells after PBS, Vehicle,
un-stimulated and activated Tregs (d) injection. Data were mean ± SD, using
the one-way ANOVA followed by Turkey post hoc comparisons. N = 5 per
group.∗p < 0.05, A-Treg vs. Vehicle and U-Treg groups.
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FIGURE 5 | Activated Tregs did not affect stroke outcomes in mice. (A) Cresyl violet staining of mice brain sections showed the infarct volume after 3 days
treatments following MCAO. The outlines indicated the infarct area. (B) Quantification of the infarct volumes. (C) Bar graph showed the mNSS test to evaluate
neurological deficiency after 3 days treatments in MCAO mice. (D) Bar graph represented the elevated body swing test scores to measure the percentage of turns to
the impaired side. Data were mean ± SD, using the one-way ANOVA followed by Turkey post hoc comparisons. N = 7–8 per group.
in the normal medium (Figures 8A,B). In contrast, the IL-
10 neutralizing antibody decreased neurosphere size compared
to the neurospheres co-cultured with activated Tregs. Taken
together, these data indicated that activated Tregs promoted NSC
proliferation via IL-10.
Discussion
In this study, we confirmed that: (1) Tregs could be isolated
from the spleen and activated by CD3e/CD28/IL-2 in vitro; (2)
Activated Tregs promoted NSC proliferation in the ipsilateral
SVZ in both normal and MCAO mice; (3) the main target stem
cells influenced by activated Tregs were type C cells; and (4) the
regulation of activated Tregs on NSC proliferation was through
IL-10 signaling.
Numerous studies demonstrated that Tregs could migrate
to the injured region after cerebral ischemia, which played
an important role for immunomodulation (Kleinschnitz et al.,
2013; Brea et al., 2014; Chu et al., 2014). Furthermore,
intravenously injecting Tregs showed neuroprotection via
suppressing immune responses (Li et al., 2013a,b). However,
these studies did not detect Tregs infiltration in the LV.
The purpose of our study was to promote neurogenesis.
We injected Tregs into the LV because NSCs located in
the SVZ, which might directly stimulate neurogenesis at that
region.
Tregs need to be activated to fully exert their
immunosuppressive function. The activated Tregs express
CD44high CD62Llow while the un-stimulated Tregs, also called
natural Tregs, express CD44low CD62Lhigh (Liston and Gray,
2014). In our experiment, CD3e/CD28/IL-2 were used to
stimulate isolated Tregs. These Tregs expressed CD44high and
CD62Llow following 3 days’ cytokine stimulation. After Treg
injection, NSC proliferation was only detected in activated Tregs
treated mice, indicating that Tregs are required to be activated
and this is an important step to affect the NSC proliferation.
The link between inflammation and neurogenesis has recently
garnered attention, with an emphasis on the impact of
immune cells on neurogenesis (Ekdahl et al., 2009; Brait et al.,
2012; Kohman and Rhodes, 2013). For instance, hippocampal
neurogenesis was significantly impaired in CD4+ T cell
immunodeficient mice and an enriched environment did not
reduce the damage (Ziv et al., 2006). Similarly, hippocampal
neurogenesis was reduced after systemic depletion of CD4+ T
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FIGURE 6 | Tregs in the LV and adjacent brain parenchyma. GFP-Tregs
stained with DAPI were presented respectively in vehicle, U-Treg and A-Treg
groups. Picture at the upper left showed the diagram of coronal brain section.
The black box represents the region we observed. The arrows showed
U-Treg-GFP and A-Treg-GFP cells.
cells and the mouse reversal learning ability tested in the Morris
water maze was greatly impaired (Wolf et al., 2009). In this
experiment, the effect of CD8+ T and B cells on neurogenesis was
not found. Current study indicated that the hippocampal stem
cell proliferation in the heterogeneous stock mice was correlated
with the ratio of CD4+/CD8+ T cells. Knockout and depleting T
cells revealed that T cells could influence neurogenesis (Huang
et al., 2010). However, the mechanism of CD4+ T cell-mediated
hippocampal neurogenesis remains unknown. The effect of
CD4+ T cell on neurogenesis could be due to a subtype of
CD4+ T cell, or cytokine production. Our results demonstrated
that activated Tregs, a subtype of CD4+ T cell, promote NSC
proliferation, providing a possibility to elucidate the function of
CD4+ T cells on neurogenesis.
In our study, activated Tregs administration did not reduce
infarct volume or improve neurobehavior in the early stage of
ischemia. Exploring the effect of activate Tregs on improvement
of neurological outcomes is interesting and important; however,
further long term experiments are needed to prove the function
of Tregs on regeneration. The short term effect of Tregs on
neurogenesis is not sufficient to improve the outcomes of MCAO
mice. Perhaps Tregs-induced neurogenesis takes time and long
term observation is needed.
Immune cell-induced neurogenesis could be caused by
secreted cytokines. For example, CD4+ T cell depletion not
only reduced Ki67+ and BrdU+ cells in the dentate gyrus, but
also decreased brain derived neurotrophic (BDNF) production
(Wolf et al., 2009). Because cytokines such as IL-4 derived
from CD4+ T cells could promote resident microglia or
neurons in dentate gyrus to secret BDNF, which could promote
focal neurogenesis (Schwartz and Shechter, 2010). Intravenous
injection of homogeneous Th17 enhanced the hippocampal stem
cell proliferation in CD4 T immunodeficient mice, suggesting
this effect was not due to the direct contact betweenNSCs and the
infiltrated Th17 cells. Further study indicated that Th17-derived
FIGURE 7 | Activated Tregs promoted NSC proliferation through IL-10
in vivo. (A) Type C and type B cells in the mouse SVZ were identified by
immunofluorescence following activated Tregs, activated Tregs plus IL-10 or
TGF-β neutralizing antibodies injecting into LV of naïve mice. BrdU double
stained with Mash1 (a–c) and GFAP (d–f) were presented respectively in
A-Treg, A-Treg/anti-IL-10 and A-Treg /anti-TGF-β group. Scale bar = 50 µm.
(B) Bar graph showed the percentage of C and B types in BrdU+ cells after in
A-Treg, A-Treg/anti-IL-10 and A-Treg /anti-TGF-β group. Data were mean ±
SD, using the one-way ANOVA followed by Turkey post hoc comparisons. N =
5 per group. ∗p < 0.05, ∗∗p < 0.01, A-Tregs vs. A-Treg/Anti-IL-10 and
A-Treg/Anti-TGF-β group.
cytokines functioned on hippocampal precursor cells (Niebling
et al., 2014).We demonstrated that Tregs could express high level
of IL-10 but not TGF-β and IL35 after activation. In addition,
neutralizing IL-10 decreased the number of BrdU+/Mash1+
cells, indicating that activated Tregs enhanced NSC proliferation
via IL-10 in vivo. The in vitro experiment also confirmed the role
of IL-10 in Treg-mediated neurosphere proliferation. Therefore,
we believe that IL-10 is a key factor in activated Treg regulation
on NSC proliferation.
Our results demonstrated that activated Tregs have a
unique feature for stimulating stem cell proliferation. We did
not detect stem cell proliferation in the un-activated Tregs
or PBS injected mice, suggesting activated Tregs is a main
stimulator. Although Bregs secret IL-10, whether Bregs involve
in IL-10 induced stem cell proliferation needs to be further
studied. Tregs play numerous roles in diseases especially in
inflammation. Tregs could protect ischemic brain injury through
many different ways, such as reducing BBB disruption and
inhibiting inflammatory response (Li et al., 2013a). Studies
also indicated that Tregs played controversial roles in ischemic
stroke; however, this effect mostly related to ischemia induced
inflammatory response. Since Tregs stimulating stem cell
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FIGURE 8 | Activated Tregs enhanced neurosphere proliferation via
IL-10 in vitro. (A) Neural spheres were observed after 3 days treatment under
inverted phase contrast microscope. a–c respectively showed the growing
states of neural sphere cultured in normal medium, co-cultured with activated
Tregs and activated Tregs plus anti-IL-10. d–f represented the magnification of
the black box in a–c. (B) The size and number of neural sphere treated with
activated Tregs and activated Tregs A-Treg plus anti-IL-10 was quantified.
Data were mean ± SD, using the one-way ANOVA followed by Turkey post
hoc comparisons. N = 6 per group. ∗p < 0.05, ∗∗p < 0.01, A-Treg group vs.
A-Treg/Anti-IL-10 and control group.
proliferation has not been studied yet, we explore this question
in this study.
Tregs played an import part in the pathophysiological process
during ischemic stroke. Tregs could migrate into the ischemic
region and regulate immune responses (Stubbe et al., 2013).
Studies showed that Tregs involved in the modulation of
neurogenesis. For instance, Tregs removal reduced the number
of Nestin+ cells after ischemic stroke (Saino et al., 2010).
Emerging studies indicated that immune cells were capable
to promote neurogenesis, mainly via the secretion of soluble
factors (Kokaia et al., 2012). Recent studies established the
role of IL-10 in neurogenesis. IL-10 overexpression in the
hippocampal neurons increased DCX+ and BrdU+/NeuN+
cells in the subgranular zone of APP/PS1 mice. Nestin, Sox1,
Sox2, Musashi, and Mash1 (pro-neural gene markers) were up-
regulated but Numb, DCX and TUBB3 were down-regulated
after IL-10 infusion (Perez-Asensio et al., 2013). This result
suggested that IL-10 has a growth factor function. It maintains
the un-differentiated status of progenitor cells and modulates
neurogenesis. Since IL-10 receptor (IL-10R) was expressed on
the NSCs (Perez-Asensio et al., 2013); IL-10 has been shown
to modulate neurogenesis through interacting with IL-10R and
thus activating downstream signaling pathway ERK and STAT3
regulated by IL-10 (Pereira et al., 2015). Furthermore, IL-
10 infusion into the LV of mouse increased the number of
Mash1+ cells (type C) and decreased the number of DCX+ cells
(type A) in SVZ (Perez-Asensio et al., 2013). In our study, it
was noted that type C cells were increased after injection of
activated Tregs. This may be due to: (1) activated Tregs mainly
secret IL-10; (2) IL-10 receptor is up-regulated in activating
proliferating cells such as type C cells. Application of IL-10
KO mice is the best way to investigate the function of IL-
10 in activated Tregs-mediated-NSC proliferation; however,
Currently IL-10 KO mice are unavailable in China. Developing
IL-10 KO mice is time-consuming. In our experiment, IL-10
neutralizing antibody was added to inhibit the function of IL-10.
We showed that IL-10 inhibition blocked the effect of activated
Tregs on NSC proliferation, which could partially explain the
critical role of IL-10 in NSC proliferation induced by activated
Tregs.
Saino’s report demonstrated that inhibiting endogenous
Tregs reduced Nestin+ cells after ischemia, suggesting that
Tregs play a role on maintaining and promoting neurogenesis
during ischemic brain injury. In our experiment, we further
demonstrated exogenous administration of Tregs could increase
BrdU+ cells in the SVZ, suggesting that both endogenous and
exogenous Tregs could promote neurogenesis. Therefore, both
enhancing endogenous Tregs and injecting exogenous Tregs can
be used for stroke therapy. Previous studies demonstrated that
IL-10 increased after cerebral ischemia, and IL-10 overexpression
could promote neurogenesis (Kiyota et al., 2012; Tobin et al.,
2014). Yet no evidence suggests that anti-IL-10 could diminish
neurogenesis. Nevertheless, IL-10 is related to neurogenesis in
the brain. Increasing IL-10 by activated Tregs is more effective
than administrating IL-10 protein itself, since the half-life of IL-
10 protein is short.
TGF-β is known for its negatively modulating neurogenesis
(Buckwalter et al., 2006). For example, blocking TGF-β increases
BrdU+ and BrdU+/CD24−/Glastin+ cells in aged and irradiated
mice, but does not change the cell number in normal
adult mice, suggesting that TGF-β inhibition could improve
neurogenesis (Pineda et al., 2013). However, the effect of TGF-β
on neurogenesis is still controversial. TGF-β overexpression
could enhance neurogenesis following gene transfection while
depletion of TGF-β receptor could also decrease neurogenesis
and stem cell migration (Mathieu et al., 2010; He et al., 2014).
Since activated Tregs were able to secret low level of TGF-β and
it might promote neurogenesis, we therefore neutralized TGF-β
to explore if it blocked NSC proliferation mediated by activated
Tregs. Our results demonstrated that TGF-β was not involved in
activated Tregs-mediated NSC proliferation.
On the basis of cell morphology, ultrastructure, andmolecular
markers, NSCs in the SVZ were divided into four cell types
(Doetsch et al., 1997; Riquelme et al., 2008): type A, proliferating
neuroblasts; type B, slowly proliferating cells; type C, actively
proliferative cells and type E, ependymal cells. Type B cells renew
themselves and become type C and A cells (Gonzales-Roybal
and Lim, 2013). Different cell types could be distinguished
using different molecular markers (Ming and Song, 2005; Kirik
and Korzhevskii, 2013): type A cells expressed DCX, PSA-
NCAM, Tuj1 and Hu; type B cells expressed GFAP; type C
cells expressed Mash1; and type E cells expressed Vimentin. We
used DCX, GFAP, Mash1 and Vimentin staining and showed
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that activated Tregs injection increased BrdU+/Mash1+ cells
in naïve mice, suggesting that Type C cells were the major
target. However, in the MCAO mice, activated Tregs increased
BrdU+/Mash1+ cells and decreased BrdU+/GFAP+ cells. This
difference between normal and ischemic mice could be due to
differentmicroenvironment.Moreover, blocking IL-10 abolished
the effect of activated Tregs on type B and C cell proliferation.
In summary, we showed that activated Tregs promoted NSC
proliferation in ipsilateral SVZ of normal and ischemic mouse
brains and blocking IL-10 abolished activated Tregs-mediated
NSC proliferation, suggesting that the activated Treg/IL-10
pathway plays a critical role in neurogenesis in the SVZ after
focal ischemia which may provide a new therapeutic approach
for ischemic stroke.
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